Targeting HER2 for localised oesophageal cancer

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F22%3A00078951" target="_blank" >RIV/00209805:_____/22:00078951 - isvavai.cz</a>
Result on the web
<a href="https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S1470204522000043?returnurl=https:%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1470204522000043%3Fshowall%3Dtrue&referrer=https:%2F%2Fpubmed.ncbi.nlm.nih.gov%2F" target="_blank" >https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S1470204522000043?returnurl=https:%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1470204522000043%3Fshowall%3Dtrue&referrer=https:%2F%2Fpubmed.ncbi.nlm.nih.gov%2F</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/S1470-2045(22)00004-3" target="_blank" >10.1016/S1470-2045(22)00004-3</a>

Result language
angličtina
Original language name
Targeting HER2 for localised oesophageal cancer
Original language description
Adenocarcinoma is now the dominant histological subtype of oesophageal cancer in high-income countries in Europe and North America. Patient outcomes have improved during the past few decades due to centralisation of surgery and implementation of multimodality therapy. However, most patients relapse following curative-intent surgery. Therefore, more effective perioperative treatment options are needed.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)